Fig. 1.

Study protocol assessing treatment-effects on tumour-free and tumour-bearing bones. For the tumour study, balb/c nude mice (female, 6 weeks) were injected with MDA-MB-231-GFP cells on day 0. All animals (including tumour-free mice) were treated on day 2 with PBS, doxorubicin (2 mg/kg i.v.), zoledronic acid (100 μg/kg s.c.) or doxorubicin followed 24 h later with zoledronic acid, animals were sacrificed on day 15 or 23.